BR112022003713A2 - Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo - Google Patents

Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo

Info

Publication number
BR112022003713A2
BR112022003713A2 BR112022003713A BR112022003713A BR112022003713A2 BR 112022003713 A2 BR112022003713 A2 BR 112022003713A2 BR 112022003713 A BR112022003713 A BR 112022003713A BR 112022003713 A BR112022003713 A BR 112022003713A BR 112022003713 A2 BR112022003713 A2 BR 112022003713A2
Authority
BR
Brazil
Prior art keywords
multimers
treatment
immunocomplex
mediated kidney
recombinant igg
Prior art date
Application number
BR112022003713A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhihui Cao Helen
SPIRIG Rolf
Zuercher Adrian
BAZ MORELLI Adriana
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of BR112022003713A2 publication Critical patent/BR112022003713A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022003713A 2019-09-13 2020-09-11 Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo BR112022003713A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19197287 2019-09-13
PCT/EP2020/075432 WO2021048330A1 (en) 2019-09-13 2020-09-11 Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders

Publications (1)

Publication Number Publication Date
BR112022003713A2 true BR112022003713A2 (pt) 2022-08-09

Family

ID=68084577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003713A BR112022003713A2 (pt) 2019-09-13 2020-09-11 Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo

Country Status (9)

Country Link
US (1) US20220332847A1 (https=)
EP (1) EP4028415A1 (https=)
JP (2) JP7734652B2 (https=)
KR (1) KR20220062084A (https=)
CN (1) CN114401985A (https=)
AU (1) AU2020344164A1 (https=)
BR (1) BR112022003713A2 (https=)
CA (1) CA3150680A1 (https=)
WO (1) WO2021048330A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
WO2013112986A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
AU2017213117A1 (en) 2016-01-27 2018-07-19 CSL Behring Lengnau AG Recombinant IgG Fc multimers
AU2017245143B2 (en) 2016-03-30 2024-01-11 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
US20210095006A1 (en) * 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

Also Published As

Publication number Publication date
JP7734652B2 (ja) 2025-09-05
US20220332847A1 (en) 2022-10-20
CN114401985A (zh) 2022-04-26
WO2021048330A1 (en) 2021-03-18
AU2020344164A1 (en) 2022-04-14
JP2022547692A (ja) 2022-11-15
CA3150680A1 (en) 2021-03-18
JP2025124714A (ja) 2025-08-26
KR20220062084A (ko) 2022-05-13
EP4028415A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
BR112018014668A2 (pt) multímeros de fc de igg recombinante
MX2021015834A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer.
ECSP18002929A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
MX2022010229A (es) Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
MX2024005705A (es) Composiciones de liquidos ionicos.
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
TN2018000021A1 (en) ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
BR112022012230A2 (pt) Variantes de progranulina
WO2016090024A3 (en) Combination therapy for treatment of cancer
MX2020007628A (es) Composiciones y metodos de uso.
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
WO2019165158A8 (en) Il-6 inhibitors and methods of treatment
EA201990988A1 (ru) Антитела против chikv и пути их применения
EP4048799A4 (en) ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR THE TREATMENT OF PROGRANULIN-ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EP4225382A4 (en) ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21
ZA202110285B (en) Antibodies and methods of use
EA202190647A1 (ru) Антитела к klrg1
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
BR112016023011A2 (pt) tratamento de câncer gástrico